Prevention of galactosamine - induced hepatic damage by the natural product loganin from the plant strychnos nux-vomica: studies on isolated hepatocytes and bile flow in rat
✍ Scribed by P. K. S. Visen; Binduja Saraswat; Kanwal Raj; A. P. Bhaduri; M. P. Dubey
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 84 KB
- Volume
- 12
- Category
- Article
- ISSN
- 0951-418X
No coin nor oath required. For personal study only.
✦ Synopsis
Loganin an iridoid glycoside extracted from the fruit of the plant, Strychnos nux-vomica, in an earlier study showed hepatoprotection in primary screening. The present detailed study has been carried out in isolated hepatocytes (ex vivo) and on bile flow (in vivo) against galactosamine induced hepatic damage in rats to determine its pharmacological potential. Loganin was given to rats at preselected doses (3, 6 and 12 mg/kg p.o. Â7). Silymarin a standard compound was given at the same doses for comparison. On day 7 galactosamine (400 mg/kg) was injected intraperitoneally. Study on isolated hepatocytes and bile flow was carried out 24 h after treatment with galactosamine. Isolation of rat hepatocytes and collection of bile were done according to standard methods. Galactosamine reduced the viability of hepatocytes as well as bile volume and bile contents. Loganin showed a dose dependent activity (14%-67%) as observed by an increase in the viability of hepatocytes and the reversal of reduced parameters of bile. The activity of silymarin a known compound was found comparable. Loganin showed significant hepatoprotective and anticholestatic activities and confirms the earlier findings. The present study warrants detailed pharmacological evaluation.